Stephane Hohn, The Hague (NL); Andrew Lennard Lewis, Camberley (GB); Sean Leo Willis, Camberley (GB); Matthew R. Dreher, West Conshohocken, PA (US); Koorosh Ashrafi, Camberley (GB); and Yiqing Tang, Camberley (GB)
Assigned to Boston Scientific Medical Device Limited, Galway (IE)
Filed by Boston Scientific Medical Device Limited, Galway (IE)
Filed on May 25, 2021, as Appl. No. 17/329,891.
Application 17/329,891 is a continuation of application No. 16/733,454, filed on Jan. 3, 2020, granted, now 11,040,104.
Application 16/733,454 is a continuation of application No. 16/243,672, filed on Jan. 9, 2019, granted, now 10,568,967, issued on Feb. 25, 2020.
Application 16/243,672 is a continuation of application No. 14/916,477, granted, now 10,350,295, issued on Jul. 16, 2019, previously published as PCT/GB2014/000352, filed on Sep. 5, 2014.
Claims priority of application No. 1315923 (GB), filed on Sep. 6, 2013.
Prior Publication US 2021/0275674 A1, Sep. 9, 2021
1. A method of treatment in which a hydrogel is administered into a blood vessel of a patient to embolize said blood vessel, the hydrogel being in the form of microspheres comprising a cross-linked polymer network that comprises polyvinyl alcohol (PVA) or a copolymer of PVA and a radiopaque species comprising one or more covalently bound iodines that are coupled to the PVA or copolymer of PVA through a cyclic acetal group and that provides the microspheres with greater than 15 mg of iodine per ml of microspheres fully hydrated in normal saline as a packed volume wherein the radiopaque species comprises an iodinated aromatic group.